Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA最新文献

{"title":"Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women.","authors":"Valeria Rella, Cinzia Rotondo, Raffaele Barile, Antonello Trotta, Francesco Paolo Cantatore, Addolorata Corrado","doi":"10.1007/s00198-026-08236-7","DOIUrl":"https://doi.org/10.1007/s00198-026-08236-7","url":null,"abstract":"<p><p>Osteoporosis is the most frequent systemic skeletal disorder characterized by an increased fracture risk and substantial global burden. While pharmacological therapies, including antiresorptive agents, anabolic agents, and dual-action agents, have demonstrated efficacy in reducing fracture risk and improving bone mineral density, long-term management remains challenging. Limitations, including treatment duration restrictions, safety concerns, rebound phenomena, and incomplete skeletal restoration, have shifted focus from prolonged monotherapy toward strategic therapeutic approaches integrating multiple agents over time. This narrative review examines current osteoporosis pharmacotherapy with emphasis on sequential and combination treatment strategies. Sequential therapy, involving strategic transitions between agents with complementary mechanisms, has emerged as optimal for maximizing and sustaining skeletal benefits. Evidence demonstrates that anabolic-to-antiresorptive sequences produce substantial bone mineral density gains and fracture risk reduction. Conversely, antiresorptive-to-anabolic transitions often result in transient bone loss and attenuated responses. Combination therapy, particularly teriparatide with denosumab, produces greater bone mineral density increases than monotherapy but remains limited by cost, uncertain fracture benefits, and potential cumulative toxicity. Current evidence supports goal-directed, individualized treatment strategies prioritizing sequencing based on fracture risk, prior therapies, and bone turnover status. Optimal regimens typically involve initial bone-forming therapy in high-risk patients, followed by antiresorptive consolidation. Future research should refine sequential protocols, identify predictive biomarkers, establish optimal durations, and conduct adequately powered fracture trials to validate strategic approaches over traditional monotherapy.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sequential romosozumab-denosumab therapy in patients on hemodialysis: association with bone mineral density improvement and TRACP-5b rebound.","authors":"Rie Kiyosumi, Kana Koinuma, Yuka Nodaira, Naofumi Ikeda","doi":"10.1007/s00198-026-08240-x","DOIUrl":"https://doi.org/10.1007/s00198-026-08240-x","url":null,"abstract":"<p><p>Osteoporosis treatment in patients undergoing maintenance dialysis remains to be established. Sequential romosozumab-to-denosumab therapy improved bone mineral density and suppressed bone turnover. Shorter transition periods were associated with reduced TRACP-5b rebound, highlighting the importance of transition management and suggesting this approach as a promising option for this high-risk population.</p><p><strong>Purpose: </strong>Patients on dialysis have a higher risk of fractures than the general population. However, osteoporosis treatment in patients on dialysis has not been established. We aimed to evaluate the efficacy of sequential therapy with romosozumab followed by denosumab and examine the clinical impact of the transition period between these agents.</p><p><strong>Methods: </strong>In this retrospective multicenter cohort study, 34 patients on maintenance dialysis received romosozumab for 12 months followed by denosumab for 12 months. Endpoints included lumbar spine and femoral neck bone mineral density and bone turnover marker levels. The transition period between the two agents was analyzed in relation to rebound of tartrate-resistant acid phosphatase 5b level.</p><p><strong>Results: </strong>Sequential therapy improved bone mineral density (lumbar spine: 0.797-0.997 g/cm²; femoral neck: 0.490-0.537 g/cm² p < 0.001) and the corresponding T-scores (lumbar spine: -2.1 to -0.9; femoral neck: -3.0 to -2.7; p < 0.001). Bone turnover marker levels also improved, including a marked decrease in tartrate-resistant acid phosphatase 5b levels. However, as both agents may induce hypocalcemia, we implemented an internal protocol involving strict monitoring of parathyroid hormone and serum calcium levels. Consequently, some patients required a longer interval before transitioning from romosozumab to denosumab. A longer transition period was associated with greater rebound of tartrate-resistant acid phosphatase 5b level, particularly when the interval exceeded 4 months.</p><p><strong>Conclusion: </strong>The sequential therapy was associated with significant improvements in bone mineral density and bone turnover marker levels among patients on dialysis. Timely transition between agents appears critical to maintain suppression of bone resorption.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis.","authors":"Tarek Haj Shehadeh, Mustapha El Zeini, Tarek Elzomor, Yusuf Rashid, Gary Updegrove, Nathan Lanham","doi":"10.1007/s00198-026-08229-6","DOIUrl":"https://doi.org/10.1007/s00198-026-08229-6","url":null,"abstract":"<p><strong>Rationale: </strong>Evaluate whether osteoporosis treatment influences osteoarthritis (OA) progression, using total shoulder arthroplasty (TSA) incidence as a proxy.</p><p><strong>Main result: </strong>Osteoporosis treatment was associated with lower TSA incidence compared with untreated patients.</p><p><strong>Significance: </strong>Findings may clarify the relationship between osteoporosis management and shoulder OA progression, informing patient counseling and management.</p><p><strong>Purpose: </strong>We evaluated in this study the impact of osteoporosis (OP) medications in patients with shoulder osteoarthritis (OA) and compared the incidence of total shoulder arthroplasty (TSA) in treated versus untreated OP patients. We hypothesized that OP medications would lead to a decreased progression of OA, manifesting as a decreased incidence of TSA.</p><p><strong>Methods: </strong>Using the TriNetX database, patients with OP diagnosed with primary shoulder OA were identified. Propensity score matching (1:1) was performed to control for relevant comorbidities, creating two cohorts of patients receiving antiresorptive therapy (denosumab or bisphosphonates) and untreated OP controls (n = 4,163 per group). A sub-analysis was conducted using similarly matched cohorts comparing denosumab versus bisphosphonates (n = 844 per group). The outcome of interest was the 5-year incidence of TSA in addition to TSA-free survival. Significance was set at p < 0.05.</p><p><strong>Results: </strong>The matched cohorts in both analyses were properly balanced. Patients receiving antiresorptive therapy demonstrated a lower 5-year incidence of TSA compared with untreated controls (1.80% vs 2.60%, p = 0.014), which was confirmed on Kaplan-Meier survival analysis (Hazard ratio HR 0.69, 95% CI 0.52-0.93). In contrast, no significant differences were observed between patients receiving denosumab and those receiving bisphosphonates in terms of 5-year TSA incidence (1.8% vs 1.4%, p = 0.561) or on Kaplan-Meier analysis (HR 1.25, 95% CI 0.58-2.67).</p><p><strong>Conclusion: </strong>OP medications in patients with shoulder OA were associated with a reduced incidence of TSA. No differences were observed between denosumab and bisphosphonates. These findings suggest a potential role for antiresorptive therapy in delaying progression of shoulder OA.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.","authors":"Tomonori Kobayakawa, Hiroto Takenaka, Takaomi Kobayashi, Yukio Nakamura","doi":"10.1007/s00198-026-08241-w","DOIUrl":"https://doi.org/10.1007/s00198-026-08241-w","url":null,"abstract":"<p><p>In a real-world study of postmenopausal women with high-risk osteoporosis, abaloparatide and romosozumab significantly improved bone mineral density and threedimensional hip structural parameters over 12 months, with no significant between-group differences observed.</p><p><strong>Purpose: </strong>Direct real-world comparisons between abaloparatide and romosozumab, particularly incorporating structural assessment beyond areal bone mineral density (BMD), remain limited.</p><p><strong>Methods: </strong>This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were included in each group. Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months. Secondary and exploratory endpoints included achievement of T-score thresholds, bone turnover markers, and DXA-based 3D-Shaper structural parameters. Longitudinal changes were assessed using mixed models for repeated measures.</p><p><strong>Results: </strong>Both groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences. The proportion of patients achieving a T-score > -2.5 increased over time in both groups without significant between-group differences. Exploratory 3D-Shaper analyses demonstrated improvements in several trabecular and cortical structural parameters over 12 months, with no significant between-group differences in any parameter.</p><p><strong>Conclusion: </strong>In this real-world propensity score-matched cohort, abaloparatide and romosozumab significantly improved BMD and proximal femur structural parameters over the first 12 months of treatment. No significant between-group differences were observed during this period.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial.","authors":"Jordi Martín Marcuello, Alessio Rodolico, María Laura Britez Carli, Mireia Puig Campmany, Marta Blazquez Andion, Julio de Caso Rodríguez, Mar Gomis Pastor, Jordi Real Gatius, Anna de Dios López, Sebastián Fradejas Moschino, Esther Pallarés, Jesús Alburquerque, María Del Mar Lluch Targarona, Jordi Mascaró Lamarca","doi":"10.1007/s00198-026-08219-8","DOIUrl":"https://doi.org/10.1007/s00198-026-08219-8","url":null,"abstract":"<p><p>A territorially coordinated, eHealth-supported Fracture Liaison Service (FLS) was implemented to standardize secondary fracture prevention across an Integrated Health Area. Following a pilot usability study, a 1-year randomized trial compared the eHealth-supported FLS with usual care in adults aged ≥ years with surgically treated femur fragility fractures. Primary outcomes included refractures and hospital readmissions, while secondary outcomes assessed functional recovery, longitudinal osteoporosis treatment prescription, treatment adherence, mortality, and professional usability of the digital platform.</p><p><strong>Purpose: </strong>Fracture Liaison Services (FLS) improve secondary fracture prevention, but implementation remains heterogeneous and digital integration is limited. We evaluated the feasibility and clinical impact of a territorially coordinated, eHealth-supported FLS standardising post-fracture care across an Integrated Health Area.</p><p><strong>Methods: </strong>This multicentre pilot project comprised two phases: an initial study evaluating a web-based platform's technical performance and usability, followed by a prospective, open-label effectiveness study randomising 119 adults aged ≥65 years with surgically treated femur fragility fractures to an eHealth-supported FLS pathway (n = 60) or usual care (n = 59). Primary outcomes were refractures and hospital readmissions; secondary outcomes included functional recovery, treatment prescription, mortality and platform usability.</p><p><strong>Results: </strong>Baseline characteristics were comparable, although the FLS group had a more favourable pre-fracture functional profile. Functional recovery was higher in the FLS group throughout follow-up, with significantly higher Barthel Index scores at 3, 6 and 12 months (80.1 vs. 61.2 at 12 months; P ≤ 0.01). Readmissions were similar and refractures infrequent, without significant differences. Osteoporosis treatment prescription was more sustained in the FLS group. All eight deaths occurred in the FLS group and none in control; given the small sample, this should not be read as a causal effect.</p><p><strong>Conclusions: </strong>A territorially coordinated, eHealth-supported FLS was feasible and was associated with better functional recovery and more sustained osteoporosis treatment prescription than usual care in the first year after femur fragility fracture. No significant differences were observed in refractures or readmissions; findings support further evaluation of digitally coordinated territorial FLS models in larger studies.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05266755, registered prospectively on 23 February 2022.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of orthogeriatric care: prescription patterns in hospitalized older adults.","authors":"Sofia Mendes-Piteira, Filipa Fialho Reis, Hugo Alexandre Ferreira, Catarina Oliveira, Francisco Serra Alves, Ana Margarida Silva, Alexandra Resende, Mariana Alves","doi":"10.1007/s00198-026-08244-7","DOIUrl":"https://doi.org/10.1007/s00198-026-08244-7","url":null,"abstract":"<p><p>Orthogeriatric co-management aims to optimize care for high-risk hip fracture patients. Implementation significantly increased secondary prevention (osteoporosis/anemia) and reduced intramuscular haloperidol. With a 63% relative reduction in mortality (8.6% to 3.2%), this model proves essential for enhancing safety and survival in complex older populations.</p><p><strong>Purpose: </strong>Proximal femoral fractures (PFF) impose a substantial burden on older adults and healthcare systems. Orthogeriatric co-management aims to optimize care for this high-risk population, yet its influence on in-hospital prescribing is poorly characterized. This study examines how implementing an orthogeriatric unit affects medication patterns in hospitalized older adults with PFF.</p><p><strong>Methods: </strong>A 23-month retrospective, observational study included consecutively admitted PFF patients aged ≥65 years. Clinical and pharmacological data (demographics, chronic medications, length of stay, surgical timing) were extracted from electronic and pharmacy records. In-hospital prescribing was assessed across key domains: analgesia, anaemia, delirium, antimicrobial stewardship, bowel regulation, and osteoporosis. Pre- and post-implementation cohorts were compared using descriptive statistics, chi-squared, and t tests (p < 0.05).</p><p><strong>Results: </strong>A total of 872 patients were included in the study. Implementation of the orthogeriatric unit was associated with significant increases in the prescription of laxatives (lactulose: 8.1% vs 74.5% p < 0.001; oral bisacodyl: 2.7% vs 48.9% p < 0.001), haematopoietic therapies (folic acid: 6.8% vs 22.0% p < 0.001; ferric carboxymaltose: 1.4% vs 20.6% p < 0.001), and secondary fracture prevention treatments (calcium: 2.7% vs 51.5% p < 0.001; vitamin D: 2.5% vs 56.7% p < 0.001; zoledronic acid: 1.4% vs 12.7% p < 0.001). Intramuscular haloperidol use significantly decreased (21.7% vs 10.9% p < 0.001). Oral paracetamol use increased, while opioid prescribing remained stable. Unadjusted intra-hospital mortality declined significantly (7.7% vs 2.9%, p = 0.005).</p><p><strong>Conclusion: </strong>The orthogeriatric approach successfully streamlined both management across key therapeutic domains and patient survival. This study quantifies the positive impact of co-management, supporting evidence for the implementation of safer, proactive therapeutic protocols in hip fracture care.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and clinical differences between individuals with and without DXA scans in Denmark.","authors":"Sally Søgaard Andersen, Annika Vestergaard Kvist, Mia Daugaard Madsen, Peter Vestergaard, Rikke Viggers","doi":"10.1007/s00198-026-08222-z","DOIUrl":"https://doi.org/10.1007/s00198-026-08222-z","url":null,"abstract":"<p><p>This study utilized two Danish registry-based cohorts to compare characteristics of DXA scanned individuals with not DXA scanned individuals. DXA scanned individuals had more comorbidities and used more medications, but there were signs of insufficient DXA scanning, particularly regarding prior major fractures and systemic glucocorticoid use.</p><p><strong>Background: </strong>Osteoporosis is increasingly prevalent, yet many high-risk individuals remain undiagnosed and unscanned with dual-energy X-ray absorptiometry (DXA). We aimed to describe DXA use in Denmark, focusing on characteristics, comorbidities, and medication use among scanned versus non-scanned individuals, and to assess changes over time by comparing 2000-2010 with 2011-2021.</p><p><strong>Methods: </strong>We conducted a nationwide cross-sectional study using two Danish registry-based cohorts: individuals with fractures and individuals with diabetes, each matched to controls without these conditions. Individuals aged ≥50 years with a first DXA scan between 2000 and 2021 were identified and compared with sex- and birth year-matched individuals without a recorded DXA scan regarding comorbidities, prior fractures, lifestyle-related risk proxies, and medication use. Descriptive statistics and standardized mean differences were used overall and across time periods.</p><p><strong>Results: </strong>We included 379,686 and 348,980 individuals with a recorded DXA and 1,571,452 and 1,736,828 individuals without a DXA from the two databases. DXA recipients were older, more often female, and had a greater burden of comorbidities, prior fractures, and use of centrally acting, cardiovascular, and anti-osteoporotic medications. These differences were more pronounced in 2011-2021. Nevertheless, a substantial proportion of individuals with major fractures or users of systemic glucocorticoids had never undergone DXA.</p><p><strong>Conclusion: </strong>DXA utilization in Denmark increasingly targets individuals at high fracture risk, yet significant gaps persist in secondary fracture prevention. Improved identification and assessment of high-risk patients - particularly those with major fractures - remain essential.</p>","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149067278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter of response to \"Postpartum timing of teriparatide initiation and BMD response in pregnancy‑ and lactation‑associated osteoporosis: an observational study\".","authors":"Christopher S Kovacs","doi":"10.1007/s00198-026-08250-9","DOIUrl":"https://doi.org/10.1007/s00198-026-08250-9","url":null,"abstract":"","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149067273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance.","authors":"Mehmet Serkan Kılıçoğlu","doi":"10.1007/s00198-026-08234-9","DOIUrl":"https://doi.org/10.1007/s00198-026-08234-9","url":null,"abstract":"","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying the clinical interpretation of AI-derived bone mineral density.","authors":"Tzu-Hao Tseng, Chen-Yu Wang, Shau-Huai Fu","doi":"10.1007/s00198-026-08198-w","DOIUrl":"https://doi.org/10.1007/s00198-026-08198-w","url":null,"abstract":"","PeriodicalId":520737,"journal":{"name":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}